Skip to content

8-KAccepted Nov 12, 4:10 PM ET

Eledon Pharmaceuticals, Inc.: reports quarter ended Sep 30, 2026

ELDNEledon Pharmaceuticals, Inc.

Accepted (ET)

4:10 PM

Nov 12, 2026

Filed

Nov 12, 2026

Documents

11

Size

452.1 KB

Summary

Eledon Pharmaceuticals, Inc.: reports quarter ended Sep 30, 2026

Updated

What happened Eledon Pharmaceuticals, Inc. announced on Nov 12, 2026 that it issued a press release regarding its quarter ended Sep 30, 2026. The 8-K states the information in the report, including the press release, is furnished to comply with the requirements of the Securities Exchange Act of 1934.

Key details

  • Item reported: Item 2.02, results of operations and financial condition.
  • Date of press release and filing: Nov 12, 2026.
  • Quarter covered: quarter ended Sep 30, 2026.
  • The report was signed on Nov 12, 2026 by David-Alexandre C. Gros, M.D., chief executive officer.

Why it may matter The filing reports Item 2.02, which covers results of operations and financial condition for the quarter ended Sep 30, 2026, and states the press release was furnished in connection with that item. This filing does not show why the insider traded or why the company acted.

AI-written summary · check the filing